Lipocine Inc.
LPCN
$7.67
$0.385.21%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.15M | 114.60K | 622.80K | 93.90K | 3.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.15M | 114.60K | 622.80K | 93.90K | 3.49M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.15M | 114.60K | 622.80K | 93.90K | 3.49M |
| SG&A Expenses | 983.40K | 767.80K | 890.40K | 1.12M | 873.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.66M | 3.48M | 3.03M | 2.18M | 1.95M |
| Operating Income | -2.52M | -3.36M | -2.40M | -2.09M | 1.55M |
| Income Before Tax | -2.37M | -3.19M | -2.21M | -1.86M | 1.78M |
| Income Tax Expenses | 0.00 | -- | -- | 200.00 | 0.00 |
| Earnings from Continuing Operations | -2.37M | -3.19M | -2.21M | -1.86M | 1.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.37M | -3.19M | -2.21M | -1.86M | 1.78M |
| EBIT | -2.52M | -3.36M | -2.40M | -2.09M | 1.55M |
| EBITDA | -2.50M | -3.35M | -2.39M | -2.07M | 1.56M |
| EPS Basic | -0.42 | -0.59 | -0.41 | -0.35 | 0.33 |
| Normalized Basic EPS | -0.26 | -0.37 | -0.26 | -0.22 | 0.21 |
| EPS Diluted | -0.42 | -0.59 | -0.41 | -0.35 | 0.31 |
| Normalized Diluted EPS | -0.26 | -0.37 | -0.26 | -0.22 | 0.20 |
| Average Basic Shares Outstanding | 5.68M | 5.41M | 5.35M | 5.35M | 5.35M |
| Average Diluted Shares Outstanding | 5.68M | 5.41M | 5.35M | 5.35M | 5.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |